Landaas & Company’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.5M | Buy |
5,954
+66
| +1% | +$14.2K | 0.27% | 33 |
|
|
2026
Q1 | $1.28M | Buy |
5,888
+983
| +20% | +$218K | 0.28% | 29 |
|
|
2025
Q4 | $1.12M | Sell |
4,905
-150
| -3% | -$34.2K | 0.25% | 35 |
|
|
2025
Q3 | $1.17M | Buy |
5,055
+100
| +2% | +$20.4K | 0.27% | 28 |
|
|
2025
Q2 | $920K | Buy |
4,955
+53
| +1% | +$9.85K | 0.22% | 33 |
|
|
2025
Q1 | $1.03M | Hold |
4,902
| – | – | 0.28% | 22 |
|
|
2024
Q4 | $871K | Buy |
4,902
+200
| +4% | +$36.8K | 0.24% | 25 |
|
|
2024
Q3 | $928K | Hold |
4,702
| – | – | 0.26% | 22 |
|
|
2024
Q2 | $806K | Buy |
4,702
+184
| +4% | +$30.5K | 0.25% | 21 |
|
|
2024
Q1 | $823K | Sell |
4,518
-885
| -16% | -$153K | 0.27% | 22 |
|
|
2023
Q4 | $838K | Buy |
5,403
+536
| +11% | +$78.1K | 0.31% | 20 |
|
|
2023
Q3 | $725K | Hold |
4,867
| – | – | 0.31% | 19 |
|
|
2023
Q2 | $656K | Sell |
4,867
-170
| -3% | -$24.9K | 0.29% | 24 |
|
|
2023
Q1 | $803K | Sell |
5,037
-200
| -4% | -$30.6K | 0.39% | 18 |
|
|
2022
Q4 | $846K | Sell |
5,237
-275
| -5% | -$42.2K | 0.47% | 14 |
|
|
2022
Q3 | $740K | Sell |
5,512
-37
| -0.7% | -$5.31K | 0.47% | 16 |
|
|
2022
Q2 | $850K | Buy |
5,549
+70
| +1% | +$10.7K | 0.52% | 15 |
|
|
2022
Q1 | $742K | Hold |
5,479
| – | – | 0.39% | 21 |
|
|
2021
Q4 | $742K | Hold |
5,479
| – | – | 0.39% | 21 |
|
|
2021
Q3 | $591K | Hold |
5,479
| – | – | 0.34% | 25 |
|
|
2021
Q2 | $617K | Sell |
5,479
-100
| -2% | -$11.3K | 0.35% | 27 |
|
|
2021
Q1 | $604K | Buy |
5,579
+250
| +5% | +$26.7K | 0.36% | 26 |
|
|
2020
Q4 | $571K | Hold |
5,329
| – | – | 0.39% | 24 |
|
|
2020
Q3 | $467K | Sell |
5,329
-6,152
| -54% | -$579K | 0.35% | 25 |
|
|
2020
Q2 | $1.13M | Buy |
11,481
+100
| +0.9% | +$8.8K | 0.9% | 13 |
|
|
2020
Q1 | $935K | Hold |
11,381
| – | – | 0.79% | 13 |
|
|
2019
Q4 | $1.01M | Sell |
11,381
-436
| -4% | -$36.2K | 0.7% | 15 |
|
|
2019
Q3 | $895K | Sell |
11,817
-78
| -0.7% | -$5.35K | 0.65% | 15 |
|
|
2019
Q2 | $865K | Sell |
11,895
-194
| -2% | -$15.2K | 0.62% | 18 |
|
|
2019
Q1 | $974K | Buy |
12,089
+111
| +0.9% | +$9.08K | 0.7% | 14 |
|
|
2018
Q4 | $1.1M | Sell |
11,978
-91
| -0.8% | -$8K | 0.91% | 12 |
|
|
2018
Q3 | $1.14M | Buy |
12,069
+8
| +0.1% | +$759 | 0.89% | 12 |
|
|
2018
Q2 | $1.12M | Sell |
12,061
-93
| -0.8% | -$9.08K | 0.89% | 11 |
|
|
2018
Q1 | $1.15M | Buy |
12,154
+105
| +0.9% | +$11.5K | 1.16% | 10 |
|
|
2017
Q4 | $1.17M | Sell |
12,049
-795
| -6% | -$74.9K | 1.01% | 10 |
|
|
2017
Q3 | $1.14M | Buy |
+12,844
| New | +$978K | 1% | 10 |
|
Other funds holding ABBV
Landaas & Company's ABBV Position: Q2 2026 in Review
Landaas & Company increased its AbbVie (ABBV) stake by 1.1% in Q2 2026, buying an estimated $14.2K and bringing the position to 5,954 shares worth $1.5M. The position accounts for 0.27% of the portfolio, ranked #33.
Landaas & Company first reported a position in ABBV in Q3 2017 and has held it in 36 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Landaas & Company held 5,954 shares of AbbVie worth $1.5M as of Q2 2026.
- Landaas & Company bought 66 AbbVie shares in Q2 2026, an estimated $14.2K.
- AbbVie made up 0.27% of Landaas & Company's portfolio in Q2 2026, its #33 holding.
- Landaas & Company first reported a position in AbbVie in Q3 2017 and has held it in 36 quarters since.
- 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Landaas & Company's 13F filing for Q2 2026, filed 21 Jul 2026.